FibroBiologics, Inc. Debt Conversion, Converted Instrument, Amount
FibroBiologics, Inc. (FBLG) reported Debt Conversion, Converted Instrument, Amount of $1.90 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2024-05-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2024-05-14
- FibroBiologics, Inc. debt conversion, converted instrument, amount for the quarter ending 2023-03-31 was $1.90M.
| Period end | Debt Conversion, Converted Instrument, Amount 3 month |
|---|---|
| 2023-03-31 | $1.90M 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 |